MX348815B - Metodo para preparar clorhidrato de 1-(4-(4-(3,4-dicloro-2-fluorof enilamino)-7-metoxiquinazolin-6-iloxi)piperidin-1-il)-prop-2-en-1 -ona e intermediarios usados en el mismo. - Google Patents

Metodo para preparar clorhidrato de 1-(4-(4-(3,4-dicloro-2-fluorof enilamino)-7-metoxiquinazolin-6-iloxi)piperidin-1-il)-prop-2-en-1 -ona e intermediarios usados en el mismo.

Info

Publication number
MX348815B
MX348815B MX2014003959A MX2014003959A MX348815B MX 348815 B MX348815 B MX 348815B MX 2014003959 A MX2014003959 A MX 2014003959A MX 2014003959 A MX2014003959 A MX 2014003959A MX 348815 B MX348815 B MX 348815B
Authority
MX
Mexico
Prior art keywords
methoxyquinazolin
fluorophenylamino
yloxy
piperidin
prop
Prior art date
Application number
MX2014003959A
Other languages
English (en)
Spanish (es)
Other versions
MX2014003959A (es
Inventor
Chan Bang Keuk
Ho Moon Young
Kil Chang Young
Original Assignee
Hanmi Science Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48044309&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX348815(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Science Co Ltd filed Critical Hanmi Science Co Ltd
Publication of MX2014003959A publication Critical patent/MX2014003959A/es
Publication of MX348815B publication Critical patent/MX348815B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2014003959A 2011-10-05 2012-10-05 Metodo para preparar clorhidrato de 1-(4-(4-(3,4-dicloro-2-fluorof enilamino)-7-metoxiquinazolin-6-iloxi)piperidin-1-il)-prop-2-en-1 -ona e intermediarios usados en el mismo. MX348815B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020110101422A KR101272613B1 (ko) 2011-10-05 2011-10-05 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온 염산염의 제조 방법 및 이에 사용되는 중간체
PCT/KR2012/008077 WO2013051883A2 (en) 2011-10-05 2012-10-05 Method for preparing 1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)-prop-2-en-1-one hydrochloride and intermediates used therein

Publications (2)

Publication Number Publication Date
MX2014003959A MX2014003959A (es) 2014-05-14
MX348815B true MX348815B (es) 2017-06-30

Family

ID=48044309

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014003959A MX348815B (es) 2011-10-05 2012-10-05 Metodo para preparar clorhidrato de 1-(4-(4-(3,4-dicloro-2-fluorof enilamino)-7-metoxiquinazolin-6-iloxi)piperidin-1-il)-prop-2-en-1 -ona e intermediarios usados en el mismo.

Country Status (23)

Country Link
US (1) US8859767B2 (https=)
EP (2) EP3611172A1 (https=)
JP (1) JP5805880B2 (https=)
KR (1) KR101272613B1 (https=)
CN (2) CN103857672B (https=)
AU (1) AU2012319291B2 (https=)
BR (1) BR112014007718B1 (https=)
CA (1) CA2850055C (https=)
CY (1) CY1122758T1 (https=)
DK (1) DK2763981T3 (https=)
ES (1) ES2775197T3 (https=)
HR (1) HRP20200426T1 (https=)
HU (1) HUE048798T2 (https=)
IL (3) IL231911B (https=)
IN (1) IN2014DN03447A (https=)
LT (1) LT2763981T (https=)
MX (1) MX348815B (https=)
PL (1) PL2763981T3 (https=)
PT (1) PT2763981T (https=)
RS (1) RS60118B1 (https=)
RU (1) RU2563630C1 (https=)
SI (1) SI2763981T1 (https=)
WO (1) WO2013051883A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101317809B1 (ko) 2011-06-07 2013-10-16 한미약품 주식회사 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물
KR20140096571A (ko) 2013-01-28 2014-08-06 한미약품 주식회사 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온의 제조방법
CN104513229A (zh) 2013-09-28 2015-04-15 正大天晴药业集团股份有限公司 喹唑啉衍生物及其制备方法
WO2016150340A1 (zh) 2015-03-20 2016-09-29 正大天晴药业集团股份有限公司 喹唑啉衍生物的盐及其制备方法
BR112021004527A2 (pt) * 2018-09-14 2021-06-08 Spectrum Pharmaceuticals, Inc. kits e métodos para tratamento contra câncer
KR101950942B1 (ko) * 2019-01-28 2019-02-22 한미약품 주식회사 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온의 제조방법
US20210221792A1 (en) * 2020-01-16 2021-07-22 Hanmi Pharm Co., Ltd. Convergent synthesis of poziotinib derivative
US20220064145A1 (en) * 2020-08-28 2022-03-03 Hanmi Science Co., Ltd. Synthesis of poziotinib derivative

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI324597B (en) * 2002-03-28 2010-05-11 Astrazeneca Ab Quinazoline derivatives
CN1882570B (zh) * 2003-09-19 2010-12-08 阿斯利康(瑞典)有限公司 喹唑啉衍生物
GB0322409D0 (en) * 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
JP2009518450A (ja) * 2005-12-12 2009-05-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 二環式複素環化合物、その化合物を含む薬剤、その使用及び製造方法
TWI377944B (en) * 2007-06-05 2012-12-01 Hanmi Holdings Co Ltd Novel amide derivative for inhibiting the growth of cancer cells
KR20120007059A (ko) * 2009-04-23 2012-01-19 아스트라제네카 아베 4―(3―클로로―2―플루오로―아닐리노)―7―메톡시―6―[[1―(n―메틸카르바모일메틸)―피페리딘―4―일]옥시]퀴나졸린의 제조 방법

Also Published As

Publication number Publication date
ES2775197T3 (es) 2020-07-24
KR101272613B1 (ko) 2013-06-10
CN103857672B (zh) 2018-11-30
JP2014528444A (ja) 2014-10-27
PT2763981T (pt) 2020-03-25
BR112014007718B1 (pt) 2022-02-22
EP3611172A1 (en) 2020-02-19
BR112014007718A2 (pt) 2017-04-25
CN103857672A (zh) 2014-06-11
RS60118B1 (sr) 2020-05-29
AU2012319291B2 (en) 2016-03-31
IN2014DN03447A (https=) 2015-06-26
KR20130037079A (ko) 2013-04-15
EP2763981A2 (en) 2014-08-13
CY1122758T1 (el) 2021-03-12
EP2763981B1 (en) 2020-01-08
RU2563630C1 (ru) 2015-09-20
LT2763981T (lt) 2020-05-25
SI2763981T1 (sl) 2020-07-31
CN110003174A (zh) 2019-07-12
CA2850055C (en) 2016-05-17
US8859767B2 (en) 2014-10-14
AU2012319291A1 (en) 2014-05-22
HRP20200426T1 (hr) 2020-09-04
IL259694A (en) 2018-07-31
EP2763981A4 (en) 2015-02-25
US20140275534A1 (en) 2014-09-18
PL2763981T3 (pl) 2020-08-10
WO2013051883A2 (en) 2013-04-11
CA2850055A1 (en) 2013-04-11
IL231911A0 (en) 2014-05-28
IL259694B (en) 2022-04-01
HUE048798T2 (hu) 2020-08-28
WO2013051883A3 (en) 2013-06-06
IL291738A (en) 2022-05-01
IL231911B (en) 2018-06-28
JP5805880B2 (ja) 2015-11-10
MX2014003959A (es) 2014-05-14
CA2850055E (en) 2013-04-11
DK2763981T3 (da) 2020-03-16

Similar Documents

Publication Publication Date Title
MX2014003959A (es) Metodo para preparar clorhidrato de 1-(4-(4-(3,4-dicloro-2-fluorof enilamino)-7-metoxiquinazolin-6-iloxi)piperidin-1-il)-prop-2-en-1 -ona e intermediarios usados en el mismo.
CO6710911A2 (es) ((r)-(e)-2-(4-(2-(5-(1-(3,5-dicloropiridin-4-il)etoxi)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol cristalino.
MY169233A (en) Solid forms of an epidermal growth factor receptor kinase inhibitor
UA110626C2 (uk) Спосіб одержання пан-інгібіторів циклінзалежної кінази формули (i), а також проміжні продукти цього процесу одержання
EP2941432B8 (en) 2-amino-6-fluoro-n-(5-fluoro-4-(4-(4-(oxetan-3-yl)piperazine-1-carbonyl)piperidin-1-yl)pyridin-3-yl)pyrazolo[1,5alpha]pyrimidine-3-carboxamide as inhibitor of atr kinase
WO2008150118A3 (en) Novel amide derivative for inhibiting the growth of cancer cells
AU2011278832A8 (en) Novel fused heterocyclic derivatives useful as c-Met tyrosine kinase inhibitors
MX386321B (es) Proceso para preparar un agente anticancerigeno, (1((-(4-fluoro-2-metilo-2h-indol-5-iloxi)-6-metoxiquinolin-7-iloxi) metilo) ciclopropanamina, su forma cristalina y sus sales.
PH12015500275A1 (en) Salts and solid forms of (s)-3-(4-((4-morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and compositions comprising and methods of using the same
MX2017007535A (es) Sistema y metodos para derivar biomarcadores de firmas geneticas de la respuesta a antagonistas de muerte programada 1 (pd-1).
MY185243A (en) Salts of an epidermal growth factor receptor kinase inhibitor
PH12012500954A1 (en) Method for producing dabigatran etexilate
PH12014500373A1 (en) Amino quinazolines as kinase inhibitors
MX2013005833A (es) Nuevos compuestos de piridina fusionada como inhibidores de caseina quinasa.
GEP20125712B (en) Method for preparation of piperazine compounds and hydrochloride salts thereof
SG10201805392YA (en) 1,2,4-triazine-6-carboxamide kinase inhibitors
MX2010000724A (es) Metodo para reducir presion intracraneal.
AR079198A1 (es) Sales de 4-(2-((5-metil-1-(2-naftalenil) -1h pirazol -3- il)oxi) etil) morfolina
IL267303B (en) Method for the production of -7-(3,4-dichloro-2-fluorophenylamino)-4)-4)-1 methoxyquinazolin-6-yloxy)piperidin-1-yl)prop-2-en-1-one
MX2014004603A (es) Formas de dosificacion solidas de 2-amino-3-(4-(2-amino-6-((r)-1-( 4-cloro-2-(3-metil-1h-pirazol-1-il)fenil)-2,2,2-trifluoroetoxi)pi rimidin-4-il)fenil) propanoato de (s)-etilo.
HK40084368A (en) Methods for preparing tyrosine receptor kinase inhibitors
EA201100683A1 (ru) Полиморфные формы 5-этокси-2-[2-(морфолино)этилтио]бензимидазол дигидрохлорида и способы их получения

Legal Events

Date Code Title Description
FG Grant or registration